HIMS Stock Slides Overnight: Retail Bets On Peptides Comeback As Stanford Neuroscientist Joins Board

What happened

Hims & Hers plans to launch Peptides+ by November’s end, offering personalized prescriptions for sermorelin, glutathione, NAD+ and B12 through independent clinicians and licensed pharmacies, with regular blood testing and ongoing care. Stanford neuroscientist Andrew Huberman has joined the company’s board.

Confirmed

Global impact / market context

Peptides+ could create a new source of sales, but the company says peptide revenue will not be material in the fourth quarter and plans to scale investment in stages. That limits near-term revenue potential while leaving future costs, demand and profitability uncertain.

Analyst inference

The article links the share decline to disappointing earnings, while describing retail traders’ hopes that Peptides+ and the new board member could support a recovery. The program’s limited published evidence and undisclosed prices leave its customer demand and profit per sale unclear.

Analyst inference

What to watch

1. Watch for the planned Peptides+ launch by November’s end and details of its prescriptions, testing and ongoing care, which will show how the service is delivered. Confirmed
2. The company has not disclosed membership prices; any later pricing will help indicate whether its affordability goal can attract customers while covering treatment and care costs. Confirmed
3. Future peptide revenue and staged investment will show whether customer interest turns into meaningful sales without costs outpacing revenue, but no launch results are provided yet. Analyst inference

Evidence

• stocktwits.com